Description
Key facts
Detection method:Fluorescent,
Sample types:Cell culture supernatant, Citrate plasma, EDTA Plasma, Heparin Plasma, Serum, Urine,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 7.2 pg/mL,
Range:7.8 - 2000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)
Product details:
Apolipoprotein AII (ApoA2)
in vitro
CatchPoint SimpleStep ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Apolipoprotein AII (ApoA2) protein in human serum, plasma, urine, and cell culture supernatant samples.
This CatchPoint SimpleStep ELISA kit has been
optimized for Molecular Devices Microplate Readers
. Click
for a list of recommended Microplate Readers.
If using a Molecular Devices' plate reader supported by SoftMax® Pro software, a preconfigured protocol for these CatchPoint SimpleStep ELISA Kits is available with all the protocol and analysis settings at
www.softmaxpro.org
The CatchPoint SimpleStep ELISA employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. CatchPoint HRP Development Solution containing the Stoplight Red Substrate is added. During incubation, the substrate is catalyzed by HRP generating a fluorescent product. Signal is generated proportionally to the amount of bound analyte and the intensity is measured in a fluorescence plater reader at 530/570/590 nm Excitation/Cutoff/Emission.
Apolipoprotein AII may stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism. ApoA2 forms a disulfide-linked homodimer. Apolipoprotein AII also forms a disulfide-linked heterodimer with APOD and interacts with HCV core protein, APOA1BP and NDRG1.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Apolipoprotein A-II (also known as ApoA-II or Apolipoprotein A2) is a pivotal protein component of high-density lipoproteins (HDL) in the plasma. It is encoded by the APOA2 gene in humans and displays a molecular mass of approximately 17.4 kDa. Apolipoprotein A-II is primarily expressed in the liver and secreted into the bloodstream where it plays a direct role in lipid metabolism. Its structural composition includes a highly amphipathic α-helical structure that facilitates interaction with lipids aiding in lipoprotein formation and stability.
Biological function summary
Apolipoprotein A-II serves as a significant regulator of HDL metabolism and lipid transport. It is an integral part of HDL particles contributing to their stability and function. Apolipoprotein A-II influences lecithin-cholesterol acyltransferase (LCAT) activity which affects cholesterol esterification. Although less studied than its counterpart Apolipoprotein A-I ApoA-II's interaction with lipids and proteins such as CETP (cholesteryl ester transfer protein) suggests its involvement in lipid exchange and reverse cholesterol transport processes.
Pathways
Apolipoprotein A-II impacts the reverse cholesterol transport pathway and lipid metabolic processes. ApoA-II works closely with its relative Apolipoprotein A-I both part of the same HDL complex. Together they play essential roles in maintaining cholesterol homeostasis and promoting cholesterol efflux from cells back to the liver. The mechanism by which it modulates the function of lipoprotein lipase and hepatic lipase further implicates its role in lipid metabolism and energy balance processes.
Dysfunction or abnormal levels of Apolipoprotein A-II have associations with cardiovascular diseases and metabolic syndromes. Altered ApoA-II levels correlate with an increased risk of atherosclerosis as its imbalance can drive perturbations in HDL composition and function. Moreover research links Apolipoprotein A-II with insulin resistance linking it with ApoA-I imbalanced lipid transport and metabolism in obesity and diabetes contexts. Understanding these connections may guide therapeutic strategies targeting ApoA-II to mitigate the risks and progression of these disorders.
